BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kura Oncology\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Kura Oncology\, Inc.'s drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07623616-2835@assetmemo.bio
DTSTAMP:20261121T010843Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ziftomenib: Phase 2 readout est. (NCT07623616)
DESCRIPTION:Ziftomenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM
 1-Mutated Acute Myeloid Leukemia\nEstimated primary completion: March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07623616
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04067336-2835@assetmemo.bio
DTSTAMP:20261121T010843Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT04067336)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: First 
 in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leuke
 mia\nEstimated primary completion: 16 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04067336
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2835@assetmemo.bio
DTSTAMP:20261121T010843Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Ziftomenib: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Ziftomenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies 
 to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With U
 ntreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
